The FDA approved our sixth health literate patient label developed with iterative patient input, and we were recognized as the second runner-up for the Healthcare Compliance Packaging Council’s “package of the year” for our antiviral medicine used to help prevent cytomegalovirus (CMV) infection after a stem cell (bone marrow) transplant from a donor.